-
Product Insights
NewSea Lion – Phase 2 Upstream Project , Falkland Islands
Empower your strategies with our Sea Lion - Phase 2 Upstream Project , Falkland Islands report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain a gateway to actionable insights and competitive advantage....
-
Innovation Ranking
Innovation Ranking – Sea Ltd
Sea Ltd (Sea) carries out the development of platforms for online, mobile entertainment, and communication for users. Its entertainment platform enables users to access mobile and online PC games, and access other entertainment content such as live streaming. The company operates an e-commerce platform that connects buyers and sellers. It also offers digital financial services such as e-wallet services, payment processing, credit-related digital financial offerings and other financial products to individuals and businesses. The company operates in China, Indonesia, Malaysia,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SEA-CD40 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SEA-CD40 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SEA-CD40 in Metastatic Melanoma Drug Details: SEA-CD40 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SEA-CD40 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SEA-CD40 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SEA-CD40 in Non-Small Cell Lung Cancer Drug Details: SEA-CD40...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SEA-CD40 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SEA-CD40 in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SEA-CD40 in Metastatic Melanoma Drug Details: SEA-CD40 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SEA-CD70 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SEA-CD70 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SEA-CD70 in Refractory Acute Myeloid Leukemia Drug Details: SEA-CD70 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SEA-CD70 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SEA-CD70 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SEA-CD70 in Relapsed Acute Myeloid Leukemia Drug Details: SEA-CD70 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SEA-CD40 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SEA-CD40 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SEA-CD40 in Non-Small Cell Lung Cancer Drug Details: SEA-CD40 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF08046040 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF08046040 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF08046040 in Refractory Acute Myeloid Leukemia Drug Details: PF-08046040...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF08046040 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF08046040 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF08046040 in Relapsed Acute Myeloid Leukemia Drug Details: PF-08046040...